Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;107:2697-2701
Published online before print May 12, 2003, doi: 10.1161/01.CIR.0000070547.88378.EA
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/21/2697    most recent
01.CIR.0000070547.88378.EAv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michaels, A. D.
Right arrow Articles by Chatterjee, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michaels, A. D.
Right arrow Articles by Chatterjee, K.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Congestive
Right arrow Cardiovascular Pharmacology
Right arrow Coronary imaging: angiography/ultrasound/Doppler/CC

(Circulation. 2003;107:2697.)
© 2003 American Heart Association, Inc.


Clinical Investigation and Reports

Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen Uptake

Andrew D. Michaels, MD; Andrew Klein, MD; James A. Madden, RN; Kanu Chatterjee, MB, FRCP

From the Division of Cardiology, Department of Medicine, University of California at San Francisco Medical Center, San Francisco, Calif.

Correspondence to Andrew D. Michaels, MD, FACC, Division of Cardiology, University of California at San Francisco Medical Center, 505 Parnassus Ave, Box 0124, San Francisco, CA 94143-0124. E-mail andrewm{at}itsa.ucsf.edu

Background— Nesiritide, recombinant human B-type natriuretic peptide, has been shown to be efficacious in the treatment of decompensated heart failure. The effects of intravenous nesiritide on the human coronary vasculature have not been studied.

Methods and Results— Ten patients underwent right and left heart catheterization. Baseline coronary blood flow was determined using quantitative coronary angiography (QCA) and an intracoronary Doppler-tipped guidewire. Myocardial oxygen uptake was measured using a coronary sinus catheter. Patients then received an intravenous infusion of nesiritide (2 µg/kg bolus followed by 0.01 µg/kg per min infusion) for 30 minutes. Right atrial pressure decreased 52% (P=0.012), pulmonary artery mean pressure decreased 19% (P=0.03), pulmonary capillary wedge pressure decreased 46% (P=0.002), and mean arterial pressure decreased 11% (P=0.007). QCA demonstrated a 15% increase in coronary artery diameter from a baseline of 2.6±0.8 to 3.0±0.8 mm at 30 minutes (P=0.007). The coronary velocity measure of average peak velocity increased 14% from 20.8±6.4 at baseline to 23.8±7.2 cm/s at 5 minutes (P=0.015) and then returned to baseline for the remainder of the infusion. Coronary blood flow increased 35% (P=0.007), whereas coronary resistance decreased 23% at 15 and 30 minutes (P=0.036). Myocardial oxygen uptake decreased 8% during the nesiritide infusion (P=0.043).

Conclusions— Nesiritide exerts coronary vasodilator effects on both the coronary conductance and resistance arteries. Despite a decrease in coronary perfusion pressure, coronary artery blood flow is increased, coronary resistance is decreased, and myocardial oxygen uptake is decreased.


Key Words: natriuretic peptides • vasodilation • hemodynamics • heart failure • blood flow




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. Belluardo, A. Cataliotti, L. Bonaiuto, E. Giuffre, E. Maugeri, P. Noto, G. Orlando, G. Raspa, B. Piazza, L. Babuin, et al.
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1529 - H1535.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. P. Salzberg, F. Filsoufi, A. Anyanwu, K. von Harbou, A. Gass, S. P. Pinney, A. Carpentier, and D. H. Adams
High-Risk Mitral Valve Surgery: Perioperative Hemodynamic Optimization with Nesiritide (BNP)
Ann. Thorac. Surg., August 1, 2005; 80(2): 502 - 506.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. D. Michaels, B. McKeown, M. Kostal, K. T. Vakharia, M. V. Jordan, I. L. Gerber, E. Foster, and K. Chatterjee
Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake
Circulation, March 29, 2005; 111(12): 1504 - 1509.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
L. E. Samuels, E. C. Holmes, and L. Letwin
Nesiritide as an adjunctive therapy in adult patients with heart failure undergoing high-risk cardiac surgery
J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 627 - 629.
[Full Text] [PDF]